Last reviewed · How we verify
NCT05583383
A Study of the Advanced Adenocarcinoma of Stomach and Gastroesophageal Junction With Camrelizumab+SOX Control Camrelizumab+SOX+ Trastuzumab
NA trial testing camrelizumab in Advanced Gastric Adenocarcinoma in 62 participants. Status unknown.
31 March 2025
Quick facts
| Lead sponsor | Henan Cancer Hospital |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 62 |
| Start date | 31 March 2022 |
| Primary completion | 31 March 2025 |
| Estimated completion | 31 March 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- camrelizumab — full drug profile →
Conditions studied
- Advanced Gastric Adenocarcinoma — all drugs for Advanced Gastric Adenocarcinoma →
Sponsor
Henan Cancer Hospital
Who can join
Adults 18 to 75, any sex, with Advanced Gastric Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A Study of the Advanced Adenocarcinoma of Stomach and Gastroesophageal Junction With Camrelizumab+SOX Control Camrelizumab+SOX+ Trastuzumab
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Comprehensive multi-omics analysis of resectable locally advanced gastric cancer: Assessing response to neoadjuvant camrelizumab and chemotherapy in a single-center, open-label, single-arm phase II trial.
Zhao Y, Li D, Zhuang J, Li Z, et al · · 2024 · cited 15× · PMID 38685486 · DOI 10.1002/ctm2.1674
Verify or expand the search:
- PubMed search for NCT05583383
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of camrelizumab
Trials testing the same drug.
- NCT07312578 — Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma · Phase 2 · enrolling by invitation
- NCT06530082 — A Single Arm Clinical Study of Dendritic Cell Vaccine Loaded With Circular RNA Encoding Cryptic Peptide for Patients Wit · Phase 1 · not yet recruiting
- NCT06363825 — A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
- NCT05624099 — Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer. · Phase 2 · recruiting
- NCT05789043 — Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma · Phase 3 · recruiting
Other recruiting trials for Advanced Gastric Adenocarcinoma
Currently open trials in the same condition.
- NCT06028737 — Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer · Phase 2, PHASE3 · recruiting
- NCT06203600 — Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial · Phase 2, PHASE3 · recruiting
- NCT05677490 — mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Neg · Phase 3 · recruiting
- NCT05041153 — Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma · EARLY_PHASE1 · recruiting
- NCT04209686 — Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma · Phase 2 · active not recruiting
Other Henan Cancer Hospital trials
Trials by the same sponsor.
- NCT07442890 — A Cohort Study on the Prevention of Nausea and Vomiting Induced by Concurrent Chemoradiotherapy for Lung Cancer Using Ro · NA · not yet recruiting
- NCT07472621 — Real-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma · not yet recruiting
- NCT07459608 — Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Indolent Lymphoma · Phase 2 · not yet recruiting
- NCT07400575 — Anlotinib in Cross-line Treatment of NSCLC and SCLC · not yet recruiting
- NCT07332221 — Application of Toripalimab as Adjuvant Therapy After Esophageal Cancer Surgery: A Multicenter Clinical Trial · Phase 3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05583383 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Henan Cancer Hospital
- Last refreshed: 17 October 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05583383.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing